-
公开(公告)号：WO2019089641A1
公开(公告)日：2019-05-09
申请号：PCT/US2018/058277
申请日：2018-10-30
申请人： EISAI R&D MANAGEMENT CO., LTD. , AIRD, Daniel , CORSON, Laura , ZHU, Ping , WARMUTH, Markus , BUONAMICI, Silvia , SMITH, Peter Gerard , FEKKES, Peter
发明人： AIRD, Daniel , CORSON, Laura , ZHU, Ping , WARMUTH, Markus , BUONAMICI, Silvia , SMITH, Peter Gerard , FEKKES, Peter
摘要： The present disclosure provides pharmaceutical combinations comprising at least one spliceosome modulator and at least one inhibitor chosen from BCL2, BCL2/BCLxL, and BCLxL inhibitors. Also provided are methods of treating cancer comprising administering a therapeutically effective amount of at least one spliceosome modulator and a therapeutically effective amount of at least one inhibitor chosen from BCL2, BCL2/BCLxL, and BCLxL inhibitors.
-
公开(公告)号：WO2018098305A1
公开(公告)日：2018-05-31
申请号：PCT/US2017/063047
申请日：2017-11-22
申请人： EISAI R&D MANAGEMENT CO., LTD. , BOCK, Mark , HAO, Ming-Hong , KORPAL, Manav , NYAVANANDI, Vijay Kumar , PUYANG, Xiaoling , SAMAJDAR, Susanta , SMITH, Peter Gerard , WANG, John , ZHENG, Guo Zhu , ZHU, Ping , MITCHELL, Lorna Helen , LARSEN, Nicholas , RIOUX, Nathalie , PRAJAPATI, Sudeep , REYNOLDS, Dominic , O'SHEA, Morgan , SAMARAKOON, Thiwanka
发明人： BOCK, Mark , HAO, Ming-Hong , KORPAL, Manav , NYAVANANDI, Vijay Kumar , PUYANG, Xiaoling , SAMAJDAR, Susanta , SMITH, Peter Gerard , WANG, John , ZHENG, Guo Zhu , ZHU, Ping , MITCHELL, Lorna Helen , LARSEN, Nicholas , RIOUX, Nathalie , PRAJAPATI, Sudeep , REYNOLDS, Dominic , O'SHEA, Morgan , SAMARAKOON, Thiwanka
IPC分类号： C07D403/12 , C07D401/14 , C07D231/56 , C07D401/06 , A61P35/00 , A61K31/416
摘要： Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.
-
公开(公告)号：WO2018170447A1
公开(公告)日：2018-09-20
申请号：PCT/US2018/022961
申请日：2018-03-16
申请人： EISAI R&D MANAGEMENT CO., LTD. , KARR, Craig D. , KORPAL, Manav , RIOUX, Nathalie , SMITH, Peter Gerard
IPC分类号： A61K45/06 , A61K31/445 , A61K31/519 , A61P35/00
摘要： Provided herein is a combination therapy useful for the treatment breast cancer. The combination comprises an ER-alpha inhibitor and a CDK 4/6 inhibitor.
-
公开(公告)号：WO2018098251A1
公开(公告)日：2018-05-31
申请号：PCT/US2017/062978
申请日：2017-11-22
申请人： EISAI R&D MANAGEMENT CO., LTD. , BOCK, Mark , HAO, Ming-Hong , KORPAL, Manav , NYAVANANDI, Vijay Kumar , PUYANG, Xiaoling , SAMAJDAR, Susanta , SMITH, Peter Gerard , WANG, John , ZHENG, Guo Zhu , ZHU, Ping , MITCHELL, Lorna Helen , LARSEN, Nicholas , RIOUX, Nathalie
发明人： BOCK, Mark , HAO, Ming-Hong , KORPAL, Manav , NYAVANANDI, Vijay Kumar , PUYANG, Xiaoling , SAMAJDAR, Susanta , SMITH, Peter Gerard , WANG, John , ZHENG, Guo Zhu , ZHU, Ping , MITCHELL, Lorna Helen , LARSEN, Nicholas , RIOUX, Nathalie
IPC分类号： C07D209/08 , A61P35/00
摘要： Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.
-
公开(公告)号：WO2016196346A1
公开(公告)日：2016-12-08
申请号：PCT/US2016/034782
申请日：2016-05-27
发明人： BOCK, Mark , HAO, Ming-Hong , KORPAL, Manav , NYAVANANDI, Vijay Kumar , PUYANG, Xiaoling , SAMAJDAR, Susanta , SMITH, Peter Gerard , WANG, John , ZHENG, Guo Zhu , ZHU, Ping
IPC分类号： A61K31/4439 , C07D317/02 , C07D317/06 , C07D487/04
CPC分类号： C07D231/56 , C07D401/06 , C07D401/14 , C07D403/06 , C07D403/12 , C07D471/14
摘要： Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.
摘要翻译： 本文公开了化合物或其药学上可接受的盐，以及通过向有需要的受试者施用治疗有效量的化合物或其药学上可接受的盐来使用该化合物治疗乳腺癌的方法。 乳腺癌可能是ER阳性乳腺癌，和/或需要治疗的受试者可以表达突变型ER-α蛋白。
-
公开(公告)号：WO2016196342A1
公开(公告)日：2016-12-08
申请号：PCT/US2016/034774
申请日：2016-05-27
发明人： HAO, Ming-Hong , KORPAL, Manav , NYAVANANDI, Vijay Kumar , PUYANG, Xiaoling , SAMAJDAR, Susanta , SMITH, Peter Gerard , WANG, John , ZHENG, Guo Zhu , ZHU, Ping
IPC分类号： C07C215/46 , A61K31/133
CPC分类号： C07C255/54 , C07C237/16 , C07C2601/04 , C07D213/30 , C07D213/64 , C07D213/73
摘要： Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.
摘要翻译： 本文公开了化合物或其药学上可接受的盐以及使用该化合物治疗乳腺癌的方法，其通过向有需要的受试者施用治疗有效量的化合物或其药学上可接受的盐来实现。 乳腺癌可以是ER阳性乳腺癌和/或需要治疗的受试者可以表达突变型ER-α蛋白。
-
公开(公告)号：WO2016196337A1
公开(公告)日：2016-12-08
申请号：PCT/US2016/034764
申请日：2016-05-27
发明人： BOCK, Mark , HAO, Ming-Hong , KORPAL, Manav , NYAVANANDI, Vijay Kumar , PUYANG, Xiaoling , SAMAJDAR, Susanta , SMITH, Peter Gerard , WANG, John , ZHU, Ping , ZHENG, Guo Zhu
IPC分类号： A61K31/00
CPC分类号： C07D231/56 , C07D401/06 , C07D401/14 , C07D403/06 , C07D403/12 , C07D471/14
摘要： Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.023 秒)
